Pharma BD Deal Intelligence
A $55.3M all-stock acquisition that ended in mutual bankruptcy: BioTransplant and Eligix jointly filed Chapter 11 within 22 months, and the HDM cell-separation assets were fire-sold to Miltenyi Biotec for just $450,000.
Acquirer and target jointly filed bankruptcy within 22 months of closing; the acquired asset was liquidated for a $450K fire-sale price.
Full analysis, sources & comparables →BioTransplant CEO Elliot Lebowitz framed the $55.3M stock deal as bringing 'complementary management and complementary technologies,' giving BioTransplant…
BioTransplant has signed a definitive agreement to acquire Eligix; the addition adds two late-stage pipeline products expected to add near-term European…
BioTransplant and its Eligix subsidiary filed Chapter 11; the Eligix HDM Cell Separation System was sold to Miltenyi Biotec for $450,000 plus 4-10% royalties —…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
6.6M BioTransplant shares for Eligix. Below $250M threshold but strategically notable: Harvard-affiliated cell-therapy/stem-cell graft purification (BCell-HDM, TCell-HDM).
Acquirer and target jointly filed bankruptcy within 22 months of closing; the acquired asset was liquidated for a $450K fire-sale price.
Assessment window: 15yr post-close.
Autologous and allogeneic stem cell transplantation is used to rescue patients with lymphoma, multiple myeloma, leukemia and other hematologic malignancies after high-dose chemotherapy. Outcomes depend on engrafting healthy stem cells while minimizing residual malignant B cells (autologous setting) and graft-versus-host disease-causing T cells (allogeneic setting), making selective ex-vivo graft purification a critical workflow.
Eligix's HDM Cell Separation Systems used monoclonal antibodies to selectively remove malignant B cells (BCell-HDM) from autologous lymphoma/myeloma grafts and GvHD-causing T cells (TCell-HDM) from donor leukocyte infusions, positioning the platform alongside competing graft-engineering approaches such as Baxter's Isolex 300i CD34+ stem cell selector and Nexell/Miltenyi-style magnetic-bead CD34 enrichment systems. BioTransplant intended to pair the Eligix devices with its AlloMune mixed-chimerism conditioning protocol to enable safer non-myeloablative transplantation, an approach competing with then-emerging reduced-intensity conditioning regimens at MSKCC, Fred Hutch and Stanford. The deal mattered because it gave BioTransplant late-stage products (BCell-HDM/TCell-HDM expected to enter Phase III) plus European commercial infrastructure, transforming a preclinical-heavy pipeline company into a near-term-revenue cell-therapy device player. The strategic logic unraveled by 2003: BioTransplant filed Chapter 11 and the Eligix HDM assets were sold to Miltenyi Biotec for $450,000 plus 4-10% royalties — Miltenyi's CliniMACS magnetic-bead system ultimately became the dominant graft-engineering platform globally.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BioTransplant Inc. / Eligix Inc. (this deal) | 2001 | $55M | 10 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals